The company's lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to ...

Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

The FDA granted regenerative medicine advanced therapy designation to ATSN-201, a gene therapy candidate for the treatment of ...

For more information, visit ClinicalTrials.gov (Identifier: NCT05878860). About X-linked Retinoschisis (XLRS) XLRS is a monogenic X-linked disease caused by mutations in the RS1 gene which encodes ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid ...

Durham, North Carolina Thursday, April 17, 2025, 12:00 Hrs [IST] ...

Abeona Therapeutics Inc.’s ABEO share price has surged by 5.08%, which has investors questioning if this is right time to ...

The company's lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads ...

The company’s lead program is evaluating ATSN-201 in an ongoing Phase I/II clinical trial for X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to ...

Correspondence to: Satoshi Ishiko Department of Ophthalmology, Asahikawa Medical College, 2-1 Midorigaoka Higashi, Asahikawa, 078-8316, Japan; ishikoasahikawa-med.ac.jp Juvenile X linked retinoschisis ...